Family planning providers' role in offering PrEP to women
- PMID: 29408284
- PMCID: PMC6010195
- DOI: 10.1016/j.contraception.2018.01.007
Family planning providers' role in offering PrEP to women
Abstract
Pre-exposure prophylaxis (PrEP) provides a radically different HIV prevention option for women. Not only is PrEP the first discrete, woman-controlled method that is taken in advance of exposure, but it is both safe and highly effective, offering over 90% protection if taken daily. While multiple modalities of PrEP are in development ranging from vaginal rings to injectables and implants, only PrEP with oral tenofovir/emtricitabine is currently FDA-approved. Family planning clinics provide key access points for many women to learn about and obtain PrEP. By incorporating PrEP services into family planning care, family planning providers have the opportunity to meet women's expectations, ensure women are aware of and offered comprehensive HIV prevention options, and reverse emerging disparities in PrEP access. Despite real and perceived barriers to integrating PrEP into family planning care, providing PrEP services, ranging from education to onsite provision, is not only possible but an important component of providing high-quality sexual and reproductive healthcare to women. Lessons learned from early adopters will help guide those in family planning settings initiating or enhancing PrEP services.
Keywords: Family planning; HIV prevention; PrEP; Women.
Copyright © 2018. Published by Elsevier Inc.
References
-
- Pre-exposure prophylaxis for the prevention of HIV infection in the United States—2014 a clinical practice guideline. Atlanta, GA: Centers for Disease Control and Prevention; 2014.
-
- Smith DK, Van Handel M, Wolitski RJ, et al. Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition - United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1291–5. - PubMed
-
- Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K. FTC/TDF (Truvada) for HIV Pre-exposure Prophylaxis (PrEP) Utilization in the United States: 2012-2015. Oral abstract TUAX0105LB presented at 21st International AIDS Conference. Durban South Africa 2016. J Int AIDS Soc. 2016;19(6 Suppl 5):21264. - PubMed
-
- Bush S, Magnuson D, Rawlings K, Hawkins T, McCallister S, Mera R. Racial characteristics for FTC/TDF for Pre-exposure Prophylaxis Users in the US. Boston, MA: 2016. Oral abstract # 2651 presented at ASM Microbe/ICAAC. http://www.natap.org/2016/HIV/062216_02.htm.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous